Interesting price move down. The good news is that Invex has avoided a cap raise.
But it's also reduced it's TAM from $1.6B to $1B, essentially reducing the market opportunity by about 40%. And it's going to take at least 2.5 years from here to readout.
I wouldn't read too much into this price move. Likely to track sideways and explains why the BoD figured that it was best to bank their remuneration by incentive shares rather than oppies.
Ann: Global Phase 3 Trial of Presendin to Launch in Q4 2021, page-71
-
- There are more pages in this discussion • 98 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
